Humacyte Inc

Company Profile

Humacyte Inc had its IPO on 2020-11-24 under the ticker symbol HUMAW.

The company operates in the Healthcare sector and Biotechnology industry. Humacyte Inc has a staff strength of 0 employees.

Stock update

Shares of Humacyte Inc opened at $0.88 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.82 - $0.94, and closed at $0.82.

This is a -3.48% slip from the previous day's closing price.

A total volume of 10,726 shares were traded at the close of the day’s session.

In the last one week, shares of Humacyte Inc have slipped by -0.1%.

Humacyte Inc's Key Ratios

Humacyte Inc has a market cap of $0, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months Humacyte Inc’s revenue was $1.88 million with a gross profit of $0 and an EBITDA of $-63628000. The EBITDA ratio measures Humacyte Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Humacyte Inc’s operating margin was -3819.6% while its return on assets stood at 0% with a return of equity of 0%.

In Q2, Humacyte Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 248.5%.

Humacyte Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-3.158 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Humacyte Inc’s profitability.

Humacyte Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

Humacyte Inc stock pays annual dividends of $ per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$168.11 million

Total Liabilities

$11.39 million

Operating Cash Flow

$0

Capital Expenditure

$485000

Dividend Payout Ratio

0%

Humacyte Inc ended 2024 with $168.11 million in total assets and $0 in total liabilities. Its intangible assets were valued at $168.11 million while shareholder equity stood at $61.12 million.

Humacyte Inc ended 2024 with $0 in deferred long-term liabilities, $11.39 million in other current liabilities, 10000.00 in common stock, $-486213000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $114.60 million and cash and short-term investments were $114.60 million. The company’s total short-term debt was $2,455,000 while long-term debt stood at $36.25 million.

Humacyte Inc’s total current assets stands at $120.56 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $0.00 compared to accounts payable of $2.36 million and inventory worth $0.

In 2024, Humacyte Inc's operating cash flow was $0 while its capital expenditure stood at $485000.

Comparatively, Humacyte Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.82

52-Week High

$1.24

52-Week Low

$0.3819

Analyst Target Price

$

Humacyte Inc stock is currently trading at $0.82 per share. It touched a 52-week high of $1.24 and a 52-week low of $1.24. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.8 and 200-day moving average was $0.75 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.